First UK GDPR Fine on Processor: ICO Targets Vendors
The UK Information Commissioner’s Office (ICO) has recently fined Advanced Computer Software Group Ltd £3.07 million for breaching the...
Actuate Doubles Survival in Pancreatic Cancer Trial
Actuate Therapeutics’ Phase 2 trial of elraglusib combined with gemcitabine/nab-paclitaxel (GnP) achieved its primary endpoint, demonstrating a statistically significant...
Impact Biotech’s Padeliporfin Shows Promising Interim Results in Phase 3 Study
ImPact Biotech announced interim Phase 3 trial results for Padeliporfin VTP, a treatment for low-grade upper tract urothelial cancer...
Untreated Tardive Dyskinesia Rates High in Long-Term Care
A Teva-sponsored study reveals significant care gaps for tardive dyskinesia (TD) among long-term care (LTC) residents. More than half...
Sachi Phase III Hutchmed Highlights Data at ASCO 2025
HUTCHMED announced positive interim results from its SACHI Phase III study, showing that the combination of savolitinib and osimertinib...
Allogene Therapeutics Shows Durable Responses with Allo-316 in Advanced Renal Cell Carcinoma
Allogene Therapeutics presented positive Phase 1 data from its TRAVERSE study of ALLO-316, an allogeneic CAR T therapy, for...
Replimune’s RP1 + Nivolumab Shows Promising Results in Melanoma Study
Replimune presented data from its IGNYTE trial at the 2025 ASCO meeting, showing promising results for RP1, an oncolytic...
Xilio Announces Updated Phase 2 Data for Vilastobart
Xilio Therapeutics announced updated Phase 2 clinical trial data for vilastobart, a tumor-activated anti-CTLA-4 therapy, combined with atezolizumab, in...
Harbinger Health Showcases Early Detection at ASCO 2025
Harbinger Health unveiled clinical data for its blood-based multi-cancer early detection (MCED) test at the 2025 ASCO Annual Meeting....
Vepdegestrant Improves PFS in ESR1-Mutant Breast Cancer
Arvinas and Pfizer announced positive Phase 3 VERITAC-2 trial results for vepdegestrant, a novel oral PROTAC ER degrader for...